Suppr超能文献

肥胖和低剂量口服避孕药对碳水化合物和脂质代谢的影响。

The effect of obesity and low-dose oral contraceptives on carbohydrate and lipid metabolism.

机构信息

Department of Obstetrics & Gynecology, Baylor College of Medicine, Houston, TX 77030, USA.

出版信息

Contraception. 2012 May;85(5):446-52. doi: 10.1016/j.contraception.2011.09.014. Epub 2011 Nov 12.

Abstract

BACKGROUND

Combination oral contraceptives (OCs) have little effect on carbohydrate and lipid metabolism in normal-weight women. Based on lack of change in intermediate markers, as well as results of epidemiologic studies, low-dose OCs do not increase the risk of diabetes or cardiovascular disease. Obesity is a risk factor for impaired glucose tolerance, diabetes and coronary artery disease, and most previous OC studies excluded these women; thus, we have limited information about carbohydrate and lipid metabolism in obese OC users.

STUDY DESIGN

This study compared changes in carbohydrate and lipid parameters in 71 normal-weight and 38 obese women initiating the OC. Women were randomized to two pills: 30 mcg ethinyl estradiol (EE)/150 mcg levonorgestrel (LNG) or 20 mcg EE/100 mcg LNG. Participants underwent baseline and cycle-3 measurements of fasting serum glucose; insulin; triglycerides and total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol.

RESULTS

Normal-weight and obese participants experienced similar changes in mean glucose, insulin and log homeostatic model assessment, as well as similar changes in total cholesterol, HDL and triglycerides; however, change in mean LDL (-4.9±20.6 mg/dL vs. +3.8±17.3 mg/dL) was different between the obese and normal-weight groups, respectively. Among the obese participants, change in glucose was marginally greater with the higher dose pill (p=.06); otherwise, changes between the body mass index groups were not modified by pill dose.

CONCLUSIONS

Obesity had little effect on any OC-induced changes in carbohydrate or lipid metabolism except for a borderline adverse interaction between obesity and OC dose with respect to fasting glucose and a positive interaction between obesity and OC use with respect to LDL cholesterol.

摘要

背景

在正常体重女性中,复方口服避孕药(OC)对碳水化合物和脂质代谢的影响很小。基于中间标志物无变化以及流行病学研究结果,低剂量 OC 不会增加糖尿病或心血管疾病的风险。肥胖是糖耐量受损、糖尿病和冠状动脉疾病的危险因素,大多数先前的 OC 研究都排除了这些女性;因此,我们对肥胖 OC 使用者的碳水化合物和脂质代谢知之甚少。

研究设计

本研究比较了 71 名正常体重和 38 名肥胖女性开始使用 OC 时碳水化合物和脂质参数的变化。女性被随机分为两组:30 mcg 炔雌醇(EE)/150 mcg 左炔诺孕酮(LNG)或 20 mcg EE/100 mcg LNG。参与者在基线和第 3 周期进行空腹血清葡萄糖;胰岛素;甘油三酯和总胆固醇、低密度脂蛋白(LDL)和高密度脂蛋白(HDL)胆固醇的测量。

结果

正常体重和肥胖参与者的平均血糖、胰岛素和稳态模型评估的对数变化相似,总胆固醇、HDL 和甘油三酯的变化也相似;然而,肥胖组和正常体重组的 LDL 平均变化(-4.9±20.6mg/dL 与+3.8±17.3mg/dL)不同。在肥胖参与者中,高剂量组的血糖变化略大(p=.06);否则,BMI 组之间的变化不受药丸剂量的影响。

结论

肥胖对 OC 引起的碳水化合物或脂质代谢的任何变化影响不大,除了肥胖与 OC 剂量之间在空腹血糖方面存在边缘不良相互作用,以及肥胖与 OC 使用之间在 LDL 胆固醇方面存在正相互作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验